PHILLIPS BARCLAY A

SEC source: 0001193805-26-000930 · e665633_4-phillips.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,370

Underlying: Common Stock · 25,370 shares

Expires 2036-07-05

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0001193805-26-000887 · e665607_4-phillips.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,370

Underlying: Common Stock · 25,370 shares

Expires 2036-03-27

F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

F2 · derivative.exercise_date: The option is fully vested as of March 27, 2026.

SEC source: 0001193805-25-000835 · e664603_4-phillips.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0001193805-24-000787 · e663706_4-phillips.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-06-11

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0001193805-24-000323 · e619337_4-phillips.xml · derivative · entry 6

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,959

Underlying: Common Stock · 64,959 shares

Expires not disclosed

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.expiration_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000323 · e619337_4-phillips.xml · derivative · entry 5

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2032-06-15

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000323 · e619337_4-phillips.xml · derivative · entry 4

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2031-06-10

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000323 · e619337_4-phillips.xml · derivative · entry 3

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2030-07-02

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000323 · e619337_4-phillips.xml · derivative · entry 2

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,986 shares

Expires 2029-11-14

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000323 · e619337_4-phillips.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 29,959 shares

Expires 2029-11-14

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-23-000921 · e618745_4-phillips.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2033-06-28

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0001193805-22-000972 · e621759_4-phillips.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0001193805-21-000866 · e620710_4-phillips.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-10

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0001193805-20-000798 · e619751_4-phillips.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-07-01

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0001193805-19-001465 · e619202_4-phillips.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,959

Underlying: Common Stock · 29,959 shares

Expires 2019-11-14

F1 · derivative.exercise_date: 9,986 of the options vest in monthly increments over a period of one year from the grant date, and 19,973 of the options vest in monthly increments over a period of three years from the grant date.

SEC source: 0001562180-19-000091 · primarydocument.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2029-01-02

F1 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on January 02, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

SEC source: 0001562180-18-004597 · primarydocument.xml · derivative · entry 3

PHILLIPS BARCLAY A · CIK 0001265801 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 5,000 shares

Expires 2027-12-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The shares underlying this option will vest as to 25% of the shares on the first anniversary of the commencement of the Reporting Person's employment (which began on November 13, 2017) and as to an additional 1/48th of the shares monthly thereafter, subject to the Reporting Person's continued service through the applicable vesting dates.

SEC source: 0001562180-18-004597 · primarydocument.xml · nonDerivative · entry 2

PHILLIPS BARCLAY A · CIK 0001265801 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price represents the weighted average price with a low of $39.35 and a high of $40.32. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.

SEC source: 0001562180-18-004597 · primarydocument.xml · nonDerivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001209191-17-064252 · doc4.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2027-11-13

F1 · derivative.exercise_date: The shares underlying this option will vest as to 25% of the shares on the first anniversary of the commencement of the Reporting Person's employment (which began on November 13, 2017) and as to an additional 1/48th of the shares monthly thereafter, subject to the Reporting Person's continued service through the applicable vesting dates.

SEC source: 0001209191-17-046949 · doc4.xml · nonDerivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,669

F1 · balance_after: Includes 2,057 shares acquired under the Issuer's Amended and Restated 2013 Employee Stock Purchase Plan on July 31, 2017.

SEC source: 0001209191-17-031437 · doc4.xml · nonDerivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,612

SEC source: 0001209191-17-007070 · doc4.xml · nonDerivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,612

F1 · balance_after: Includes 1,633 shares acquired under the Issuer's Amended and Restated 2013 Employee Stock Purchase Plan on January 31, 2017.

SEC source: 0001209191-16-150731 · doc4.xml · derivative · entry 2

PHILLIPS BARCLAY A · CIK 0001265801 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2026-11-14

F2 · derivative.exercise_date: Vesting of the shares subject to this option grant under the Plan is subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vesting on the first anniversary of the Grant Date, and the remaining seventy-five percent (75%) of the shares vesting in equal monthly installments over the following three (3) years subject to continued employment through such vesting date; and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares will vest if, at any time during the four-year period from the Grant Date, the volume-weighted average stock price of Novavax' common stock meets or exceeds $4.00, $6.00, or $8.00, respectively, for twenty (20) consecutive trading days.

SEC source: 0001209191-16-150731 · doc4.xml · derivative · entry 1

PHILLIPS BARCLAY A · CIK 0001265801 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2026-11-14

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. 2015 Stock Incentive Plan, as amended (the "Plan") vest on the first anniversary of the November 14, 2016 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.